| Literature DB >> 35455505 |
Olu Onyimadu1, Mara Violato2, Nerys M Astbury1, Susan A Jebb1, Stavros Petrou1.
Abstract
An economic perspective is crucial to understand the broad consequences of childhood excess weight (CEW). These can manifest in the form of elevated health care and societal costs, impaired health status, or inefficiencies in the allocation of resources targeted at its prevention, management, or treatment. Although existing systematic reviews provide summaries of distinct economic research strands covering CEW, they have a restricted focus that overlooks relevant evidence. The overarching aim of this structured review was to update and enhance recent key reviews of four strands of economic evidence in this area, namely, (1) economic costs associated with CEW, (2) health utilities associated with CEW, (3) economic evaluations of interventions targeting CEW, and (4) economic determinants and broader consequences of CEW. Our de novo searches identified six additional studies for the first research strand, five studies for the second, thirty-one for the third, and two for the fourth. Most studies were conducted in a small number of high-income countries. Our review highlights knowledge gaps across all the research strands. Evidence from this structured review can act as data input into future economic evaluations in this area and highlights areas where future economic research should be targeted.Entities:
Keywords: childhood; cost-effectiveness; cost-of-illness; economic evaluation; food price; human capital; obesity; socioeconomic; structured review; utilities
Year: 2022 PMID: 35455505 PMCID: PMC9028108 DOI: 10.3390/children9040461
Source DB: PubMed Journal: Children (Basel) ISSN: 2227-9067
Aggregate descriptive summary of economic cost studies.
| Study Characteristics | Number of Studies Identified |
|---|---|
| Year of publication | |
| 2006–2010 | 3 |
| 2011–2015 | 2 |
| 2016–2020 | 7 |
|
| |
| High-income | All |
| Low- and middle-income | None |
|
| |
| Decision-analytical models | 2 |
| Longitudinal study/panel data analysis | 6 |
|
| |
| Direct costs | 11 |
| Indirect costs | 2 |
|
| |
| Lifetime | 5 |
| 30 years | 1 |
| 10 years | 1 |
| 3 years | 1 |
| 1 year | 4 |
Descriptive analysis of the key assessment items for individual economic cost studies.
| First Author and Year of Publication | Country | Type of Study Design | Age Range upon Study Entry | Study Time Horizon | Exposures/Measures of Weight Status Compared | Type of Economic Cost(s) Estimated | Currency Unit (Price Year) | Discount Rates | Sensitivity Analyses (Further Analytical Approaches) | Estimated Economic Costs * | Quality Score (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fernandes, M.M. 2009 [ | United States | Cohort (Monte Carlo) simulation model | 9 years | Lifetime | Obese versus normal-weight | Direct costs | U.S. dollars (2008) | 3% annually | DSA and PSA | Excess lifetime costs of USD 12,047 and USD 15,639 per boy and girl, respectively | 18.5/19 (97%) |
| Lightwood, J. 2009 [ | United States | Markov model | 12 to 19 years | 30 years | Obese versus normal-weight | Direct and indirect costs | U.S. dollars (2007) | 3% annually | DSA | Projected (2020–2050) cumulative excess direct, indirect, and total costs: USD 46 billion, USD 208 billion, and USD 254 billion, respectively | 17.5/19 (92%) |
| Trasande, L. 2010 [ | United States | Cohort simulation model | 12 years | Lifetime | Obese and overweight versus normal-weight | Direct costs | U.S. dollars (2005) | 3% annually | DSA | Total direct medical expenditures (child and adult) attributable to childhood overweight/obesity for male and female is USD 2.94 billion and USD 3.3 billion, respectively | 16.5/19 (87%) |
| Ma, S. and Frick, K. D. 2011 [ | United States | Panel data analysis (two-part regression model) | 6 to 17 years | 1 year | Obese versus normal-weight | Direct costs | U.S. dollars (2006) | 3% annually | DSA (Controlled for covariates) | Excess annual medical expenditure: USD 264 per capita | 15/17 (88%) |
| Sonntag, D. 2015 [ | Germany | Markov model | 3 to 17 years | Lifetime | Obese and overweight versus normal-weight | Direct costs | Euros (2010) | 3% annually | DSA | Excess lifetime direct costs (excess weight): EUR 7028 and EUR 4262 per girl and boy, respectively | 19/19 (100%) |
| Sonntag, D. 2016 [ | Germany | Markov model | 3 to 17 years | Lifetime | Obese and overweight versus normal-weight | Indirect costs | Euros (2010) | 3% annually | DSA and PSA | Excess lifetime indirect costs (excess weight): EUR 2445 and EUR 4209 per girl and boy, respectively | 19/19 (100%) |
| Hayes A. 2016 [ | Australia | Longitudinal cohort analysis (multivariable regression analyses) | 2 to ≤5 years | 3 years | Obese and overweight versus normal-weight | Direct costs | Australian dollars (2014) | Not stated | DSA (Controlled for covariates) | Excess mean 3-year health care costs: AUD 1608 and AUD 93 for an obese and overweight child, respectively | 16/17 (94%) |
| Wijga, A.H. 2018 [ | The Netherlands | Longitudinal birth cohort analysis (Wilcoxon–Mann–Whitney test for statistical significance) | 14 to 15 | 1 year | Overweight (including obesity) and non-overweight | Direct costs | Euros (2011) | NA | None reported | Mean excess annual health care expenditure: EUR 221 | 13/16 (81%) |
| Black, N. 2018 [ | Australia | Longitudinal panel analysis (two-part regression model with IV estimator as base case) | 6 to 13 years | 1 year | Obese and overweight versus normal-weight | Direct costs | Australian dollars (2015) | NA | DSA (Controlled for covariates) | Excess annual non-hospital Medicare costs per child: AUD 63 and AUD 103 for overweight and obesity, respectively and annual medical cost due to excess weight was AUD 43 million in the full childhood population | 14/16 (88%) |
| Biener, A.I. 2020 [ | United States | Panel data analysis (two-part regression model with IV estimator as base case) | 11 to17 years | 1 year | Obesity and severe obesity versus normal-weight | Direct costs | U.S. dollars (2015) | NA | DSA (Controlled for covariates) | Per child for obesity and severe obesity, respectively, excess annual medical expenditure: USD 907 and USD 1491 and excess annual out-of-pocket expenditure: USD 25.79 and 37.36. Mean annual direct cost of obesity of USD 7.71 billion in the full childhood population | 15/16 (94%) |
| Kompaniyets, L. 2020 [ | United States | Longitudinal study (two-part regression model) | 2 to 19 years | 10 years | Primary obesity diagnosis and secondary obesity diagnosis versus no obesity diagnosis | Direct costs | U.S. dollars (2016) | Not stated | (Controlled for covariates) | Excess primary obesity diagnosis charges and costs: USD 20,879 and USD 6049, respectively. Excess secondary obesity diagnosis charges and costs: USD 3453 and USD 1359, respectively | 14/17 (82%) |
| Schell, R.C. 2020 [ | United States | Markov model | 18 years | Lifetime | Obese versus normal-weight | Direct costs | U.S. dollars (2017) | 3% annually | None reported | Excess lifetime costs: USD 22,315, USD 14,813, USD 37,329, and USD 2018 for white males, black males, white females, and black females, respectively | 17/19 (89%) |
DSA: deterministic sensitivity analysis; IV: instrumental variable; NA: not applicable; PSA: probabilistic sensitivity analysis. * Estimated costs are expressed in the original currency and price year.
Descriptive analysis of the key items on health utility values associated with childhood excess weight.
| First Author and Year of Publication | Country | Population and Age | Sample Size(s) | Type of Study | Utility Instrument (Proxy Assessment) | Preference/Valuation Method | Estimated Utility Values (or Coefficients) and Corresponding Health States | Quality Score (%) |
|---|---|---|---|---|---|---|---|---|
| Boyle, S.E., et al. 2010 [ | United Kingdom | Children aged 11 to 15 years: two groups who either achieved the recommended PA guidelines or did not | Cross-sectional study | EQ-5D-Y/VAS | United Kingdom adult general population/TTO | Healthy/normal weight: 0.9 (s.d. 0.18); Overweight or obese: 0.87 (s.d. 0.14) | 4.5/6 (75%) | |
| Belfort, M.B., et al. 2011 [ | United States | Children aged 5 to 18 years | Cross-sectional study | HUI3 (and proxy parent version for all) | Canadian general population (>16 years of age)/SG | Healthy weight: 0.81 (95% CI 0.76–0.86); Overweight or obese: 0.78 (95% CI 0.72–0.83) | 4.5/6 (75%) | |
| Keating, C.L., et al. 2011 [ | Australia | Secondary school children aged 12 to 15 years | Cross-sectional study | AQoL-6D | Recalibrated for Australian adolescents/TTO | Healthy/normal weight: 0.86 (s.d. 0.16); Overweight: 0.842 (s.d. 0.17); Obese: 0.805 (s.d. 0.18) | 4.5/6 (75%) | |
| Makkes, S., et al. 2013 [ | The Netherlands | Children aged 8 to 13 years and 13 to 19 with severe obesity | 8 to 13 years old ( | Cross-sectional estimations from the HELIOS trial | EQ-5D-3L VAS | Dutch general population/TTO | Severely obese: 0.79 (s.d. 0.22) | 4/6 (67%) |
| Trevino, R.P., et al. 2013 [ | United States | Sixth grade students (aged under 13 years and approximate average age 11 years) | Cross-sectional estimations from the HEALTHY trial | HUI2 and HUI3 | Canadian general population (>16 years of age)/SG | HUI2 BMI%: <85 0.853 (s.d. 0.157); 85–94 0.848 (s.d. 0.157); 95–99 0.838 (s.d. 0.163); and 99 + 0.814 (s.d. 0.175) and HUI3 BMI%: <85 0.805 (s.d. 0.233); 85–94 0.795 (s.d. 0.236); 95–99 0.786 (s.d. 0.242); and 99 + 0.759 (s.d. 0.245) | 6/6 (100%) | |
| Bolton, K., et al. 2014 [ | Australia | Students aged 11 to 19.6 years | Cross-sectional study (baseline data only) | AQoL-6D | Recalibrated for Australian adolescents/TTO | Healthy/normal weight: 0.89 (s.d. 0.14) and Overweight or obese: 0.87 (s.d. 0.14) | 4.5/6 (75%) | |
| Canaway, A. and E. Frew 2014 [ | United Kingdom | Children aged 6 to 7 years | Cross-sectional study | CHU-9D and EQ-5D-Y | United Kingdom adult general population/CHU-9D: SG and EQ-5D-Y: TTO | CHU-9D: Healthy/normal weight 0.87 (95% CI 0.84–0.89); Overweight 0.86 (95% CI 0.81–0.9); Obese 0.84 (95% CI 0.77–0.91); and Overweight or obese 0.85 (95% CI 0.8–0.89) and EQ-5D-Y: Healthy/normal weight 0.73 (95% CI 0.66–0.8); Overweight 0.66 (95% CI 0.43–0.83); Obese 0.69 (95% CI 0.54–0.83); and Overweight or obese 0.67 (95% CI 0.56–0.78) | 4.5/6 (75%) | |
| Chen, G., et al. 2014 [ | Australia | Primary (7 to 13 years) and secondary (13 to 17) school children | Primary schools | Cross-sectional study (baseline data only) | CHU-9D | Recalibrated for Australian adolescents/SG | Primary schools: Healthy-weight 0.87 (s.d. 0.11); Overweight 0.86 (s.d. 0.12); Obese 0.83 (s.d. 0.16) and secondary schools: Healthy-weight 0.82 (s.d. 0.12); and Overweight or obese 0.81 (s.d. 0.12) | 5/6 (83%) |
| Frew, E.J., et al. 2015 [ | United Kingdom | Children aged 5 to 6 years | Cross-sectional estimations from the WAVES trial | CHU-9D | United Kingdom adult general population/SG | Healthy weight 0.825 (s.d. 0.14); Overweight 0.811 (s.d. 0.14); Obese 0.827 (s.d. 0.13); and Overweight or obese 0.82 (s.d. 0.13) | 4.5/6 (75%) | |
| Eminson, K., et al. 2018 [ | United Kingdom | Children between 6 and 10 years old | The WAVES trial: 1350 children at baseline (Healthy weight | Longitudinal study | CHU-9D | United Kingdom adult general population/SG | In the regression results from the analyses investigating the impact of weight status on health utility, the coefficients ( | 6/6 (100%) |
| Tan, E.J., et al. 2018 [ | Australia | Children aged 5 years | Longitudinal study, but HRQoL data and analysis were cross-sectional | HUI3 (parent proxy version) | Canadian general population (>16 years of age)/SG | Healthy weight: 0.956 ( | 6/6 (100%) | |
| Hoedjes, M., et al. 2018 [ | The Netherlands | Children and adolescents ages 8 to 19 years with severe obesity: intensive lifestyle treatment | Longitudinal study | EQ-5D-3L | Dutch general population/TTO | Utility scores at baseline, after 1 year of treatment, and 1 year of follow-up were 0.80 ( | 5.5/7 (79%) | |
| Bell, L., et al. 2019 [ | Australian | 9–11-year-olds | Quasi-experimental repeat cross-sectional design | CHU-9D | Recalibrated for Australian adolescents/SG | Utility values for the intervention at baseline and end of study were 0.82 and 0.77, respectively. Utility values for the comparator at baseline and end of study were 0.80 and 0.79, respectively. Utility values not reported by weight status. | 7/7 (100%) | |
| Killedar, A., et al. 2019 [ | Australian | Two cohorts (waves 6 and 7) of boys and girls 10–17 years from the LSAC study | Girls: between | Primary data collection from a longitudinal study | CHU-9D | The best–worst scaling study conducted in an Australian adolescent population/SG | Girls: BMI z-scores −2, 1, 2, and 3 from ages 10 to 17, respectively: [10 years: 0.818; 0.812; 0.809; 0.807], [11 years: 0.814; 0.799; 0.794; 0.789], [12 years: 0.811; 0.787; 0.779; 0.771], [13 years: 0.807; 0.775; 0.764; 0.753], [14 years: 0.804; 0.762; 0.748; 0.735], [15 years: 0.800; 0.750; 0.733; 0.717], [16 years: 0.796; 0.738; 0.718; 0.698], [17 years: 0.793; 0.725; 0.703; 0.680]. Boys: BMI z-scores −2, 1, 2, and 3 from ages 10 to 17, respectively: [10 years: 0.811; 0.799; 0.795; 0.792], [11 years: 0.817; 0.806; 0.802; 0.798], [12 years: 0.824; 0.812; 0.809; 0.805], [13 years: 0.830; 0.819; 0.815; 0.811], [14 years: 0.837; 0.825; 0.822; 0.818], [15 years: 0.843; 0.832; 0.828; 0.824], [16 years: 0.850; 0.838; 0.835; 0.831], [17 years: 0.856; 0.845; 0.841; 0.837] | 7/7 (100%) |
AQoL: Assessment of Quality of Life; BMI: body mass index; CHU-9D: Child Health Utility-9 dimensions; EQ-5D: EuroQol-5 dimensions; EQ-5D-Y: EQ-5D-Youth; EQ-5D-3L: EQ-5D-3 levels; HUI2 and HUI3: Health Utilities Index version 2 and 3; LSAC: Longitudinal Study of Australian Children SG: standard gamble; TTO: time trade-off; VAS: visual analogue scale.
Aggregate descriptive summary of economic evaluation studies.
| Study Characteristics | Number of Studies Identified |
|---|---|
| Year of publication | |
| 2001–2005 | 2 |
| 2006–2010 | 11 |
| 2011–2015 | 16 |
| 2016–2020 | 34 |
|
| |
| High-income | 61 |
| Low- and middle-income | 2 |
|
| |
| Behavioural | 26 |
| Environmental | 2 |
| Policy | 2 |
| Surgical | 1 |
| Multiple categories | 32 |
|
| |
| Prevention | 37 |
| Treatment | 14 |
| Treatment and prevention | 10 |
| Management | 2 |
|
| |
| School-based | 23 |
| Health care/clinical setting | 5 |
| Family | 3 |
| Home | 2 |
| Community | 5 |
| Population | 3 |
| Multi-setting | 22 |
|
| |
| Randomised controlled trial | 27 |
| Decision-analytical | 24 |
| Multiple design (studies with two main types of designs) | 7 |
| Cross-sectional | 1 |
| Quasi-experimental | 1 |
| Non-randomised controlled trial | 1 |
| Longitudinal | 1 |
| Pilot | 1 |
|
| |
| Societal | 45 |
| Health care | 12 |
| Institutional or school system | 2 |
| Provider | 1 |
| Not stated/insufficient information | 3 |
|
| |
| Cost-effectiveness | 30 |
| Cost-utility | 11 |
| Cost-consequence | 8 |
| Cost-benefit | 3 |
| Two or more types | 11 |